BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35160296)

  • 1. Evaluation of Risk Prediction Models to Identify Cancer Therapeutics Related Cardiac Dysfunction in Women with HER2+ Breast Cancer.
    Suntheralingam S; Fan CS; Calvillo-Argüelles O; Abdel-Qadir H; Amir E; Thavendiranathan P
    J Clin Med; 2022 Feb; 11(3):. PubMed ID: 35160296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The added value of the HFA/ICOS score in the prediction of chemotherapy-related cardiac dysfunction in breast cancer.
    Di Lisi D; Madaudo C; Faro DC; Rossetto L; Triolo OF; Losi V; Galassi AR; Monte IP; Novo G
    J Cardiovasc Med (Hagerstown); 2024 Mar; 25(3):218-224. PubMed ID: 38305134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Features of trastuzumab-related cardiac dysfunction: deformation analysis outside left ventricular global longitudinal strain.
    Nhat GM; Hai NH; Duc VT; Tri HHQ; Hoa CN
    Front Cardiovasc Med; 2024; 11():1291180. PubMed ID: 38312233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nomogram for Predicting Risk of Cancer Therapy-Related Cardiac Dysfunction in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
    Yu AF; Lin IH; Jorgensen J; Copeland-Halperin R; Feldman S; Ibtida I; Assefa A; Johnson MN; Dang CT; Liu JE; Steingart RM
    J Am Heart Assoc; 2023 Oct; 12(19):e029465. PubMed ID: 37750581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer: Comparison With Echocardiography.
    Houbois CP; Nolan M; Somerset E; Shalmon T; Esmaeilzadeh M; Lamacie MM; Amir E; Brezden-Masley C; Koch CA; Thevakumaran Y; Yan AT; Marwick TH; Wintersperger BJ; Thavendiranathan P
    JACC Cardiovasc Imaging; 2021 May; 14(5):962-974. PubMed ID: 33248962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis.
    Oikonomou EK; Kokkinidis DG; Kampaktsis PN; Amir EA; Marwick TH; Gupta D; Thavendiranathan P
    JAMA Cardiol; 2019 Oct; 4(10):1007-1018. PubMed ID: 31433450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction.
    Demissei BG; Hubbard RA; Zhang L; Smith AM; Sheline K; McDonald C; Narayan V; Domchek SM; DeMichele A; Shah P; Clark AS; Fox K; Matro J; Bradbury AR; Knollman H; Getz KD; Armenian SH; Januzzi JL; Tang WHW; Liu P; Ky B
    J Am Heart Assoc; 2020 Jan; 9(2):e014708. PubMed ID: 31959034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of Integrating Heart Failure Risk Factors Into Impairment of Global Longitudinal Strain to Predict Anthracycline-Related Cardiac Dysfunction.
    Milks MW; Velez MR; Mehta N; Ishola A; Van Houten T; Yildiz VO; Reinbolt R; Lustberg M; Smith SA; Orsinelli DA
    Am J Cardiol; 2018 Apr; 121(7):867-873. PubMed ID: 29454478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer Therapeutics-Related Cardiac Dysfunction among Patients with Active Breast Cancer: A Cardio-Oncology Registry.
    Laufer-Perl M; Mor L; Milwidsky A; Derakhshesh M; Amrami N; Moshkovits Y; Arnold J; Topilsky Y; Arbel Y; Rozenbaum Z
    Isr Med Assoc J; 2020 Sep; 22(9):564-568. PubMed ID: 33236555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paraoxonase-1 Activity in Breast Cancer Patients Treated With Doxorubicin With or Without Trastuzumab.
    Thompson EW; Demissei BG; Smith AM; Brahmbhatt P; Wang J; Clark A; DeMichele A; Narayan V; Shah P; Sun L; Lefebvre B; Fradley MG; Carver JR; Tang WHW; Ky B
    JACC Basic Transl Sci; 2022 Jan; 7(1):1-10. PubMed ID: 35128203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noninvasive Measures of Ventricular-Arterial Coupling and Circumferential Strain Predict Cancer Therapeutics-Related Cardiac Dysfunction.
    Narayan HK; French B; Khan AM; Plappert T; Hyman D; Bajulaiye A; Domchek S; DeMichele A; Clark A; Matro J; Bradbury A; Fox K; Carver JR; Ky B
    JACC Cardiovasc Imaging; 2016 Oct; 9(10):1131-1141. PubMed ID: 27085442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can Quantitative CMR Tissue Characterization Adequately Identify Cardiotoxicity During Chemotherapy?: Impact of Temporal and Observer Variability.
    Altaha MA; Nolan M; Marwick TH; Somerset E; Houbois C; Amir E; Yip P; Connelly KA; Michalowska M; Sussman MS; Wintersperger BJ; Thavendiranathan P
    JACC Cardiovasc Imaging; 2020 Apr; 13(4):951-962. PubMed ID: 31864977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline Immunoglobulin E Levels as a Marker of Doxorubicin- and Trastuzumab-Associated Cardiac Dysfunction.
    Beer LA; Kossenkov AV; Liu Q; Luning Prak E; Domchek S; Speicher DW; Ky B
    Circ Res; 2016 Oct; 119(10):1135-1144. PubMed ID: 27582370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Profile and Prognosis of a Real-World Cohort of Patients With Moderate or Severe Cancer Therapy-Induced Cardiac Dysfunction.
    Esteban-Fernández A; Carvajal Estupiñan JF; Gavira-Gómez JJ; Pernas S; Moliner P; Garay A; Sánchez-González Á; Fernández-Rozas I; González-Costello J
    Front Cardiovasc Med; 2021; 8():721080. PubMed ID: 34778393
    [No Abstract]   [Full Text] [Related]  

  • 15. Monocyte-to-lymphocyte ratio as predictor of cancer therapy-related cardiotoxicity in patients with breast cancer: a pilot cohort study.
    Pivatto Júnior F; Santos ÂBS; Englert EF; Mazzutti G; Costa GOM; Saffi MAL; Liedke PER; Fritsch VH; Biolo A
    Breast Cancer Res Treat; 2023 Aug; 200(3):355-362. PubMed ID: 37273150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiotoxicity of BRAF/MEK Inhibitors: A Longitudinal Study Incorporating Contemporary Definitions and Risk Scores.
    Glen C; Adam S; McDowell K; Waterston A; Tan YY; Petrie MC; Coats CJ; Lang NN
    JACC CardioOncol; 2023 Oct; 5(5):628-637. PubMed ID: 37969652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Left atrial longitudinal strain as a predictor of Cancer therapeutics-related cardiac dysfunction in patients with breast Cancer.
    Park H; Kim KH; Kim HY; Cho JY; Yoon HJ; Hong YJ; Park HW; Kim JH; Ahn Y; Jeong MH; Cho JG
    Cardiovasc Ultrasound; 2020 Jul; 18(1):28. PubMed ID: 32693802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-dimensional speckle-tracking echocardiography for the global and regional assessments of left ventricle myocardial deformation in breast cancer patients treated with anthracyclines.
    Coutinho Cruz M; Moura Branco L; Portugal G; Galrinho A; Timóteo AT; Rio P; Ilhão Moreira R; Mendonça T; Leal A; Gameiro F; Duarte Oliveira S; Luz R; Cruz Ferreira R
    Clin Res Cardiol; 2020 Jun; 109(6):673-684. PubMed ID: 31559482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arginine-Nitric Oxide Metabolites and Cardiac Dysfunction in Patients With Breast Cancer.
    Finkelman BS; Putt M; Wang T; Wang L; Narayan H; Domchek S; DeMichele A; Fox K; Matro J; Shah P; Clark A; Bradbury A; Narayan V; Carver JR; Tang WHW; Ky B
    J Am Coll Cardiol; 2017 Jul; 70(2):152-162. PubMed ID: 28683962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early electrocardiographic indices for predicting chronic doxorubicin-induced cardiotoxicity.
    Kinoshita T; Yuzawa H; Natori K; Wada R; Yao S; Yano K; Akitsu K; Koike H; Shinohara M; Fujino T; Shimada H; Ikeda T
    J Cardiol; 2021 Apr; 77(4):388-394. PubMed ID: 33214049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.